Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
High Blood Pressure & Cardiovascular Prevention
Erschienen in: High Blood Pressure & Cardiovascular Prevention 4/2016

01.12.2016 | Review Article

The Pathophysiological Role of NOX2 in Hypertension and Organ Damage

verfasst von: Maurizio Forte, Cristina Nocella, Elena De Falco, Silvia Palmerio, Leonardo Schirone, Valentina Valenti, Giacomo Frati, Roberto Carnevale, Sebastiano Sciarretta

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

NADPH oxidases (NOXs) represent one of the major sources of reactive oxygen species in the vascular district. Reactive oxygen species are responsible for vascular damage that leads to several cardiovascular pathological conditions. Among NOX isoforms, NOX2 is widely expressed in many cells types, such as cardiomyocytes, endothelial cells, and vascular smooth muscle cells, confirming its pivotal role in vascular pathophysiology. Studies in mice models with systemic deletion of NOX2, as well as in transgenic mice overexpressing NOX2, have demonstrated the undeniable involvement of NOX2 in the development of hypertension, atherosclerosis, diabetes mellitus, cardiac hypertrophy, platelet aggregation, and aging. Of note, the inhibition of NOX2 has been found to be protective for cardiovascular homeostasis. Here, we review the evidence demonstrating that the modulation of NOX2 activity is able to improve vascular physiology, suggesting that NOX2 may be a potential target for therapeutic applications.
Literatur
1.
Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arter Thromb Vasc Biol. 2005;25:29–38.CrossRef
2.
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–4.CrossRefPubMed
3.
Förstermann U. Nitric oxide and oxidative stress in vascular disease. Pflügers Arch. 2010;459:923–39.CrossRefPubMed
4.
Li J-M, Mullen AM, Yun S, et al. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res. 2002;90:143–50.CrossRefPubMed
5.
Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II: role of the p47phox subunit. J Biol Chem. 2003;278:12094–100.CrossRefPubMed
6.
Görlach A, Brandes RP, Nguyen K, et al. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26–32.CrossRefPubMed
7.
Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91:1160–7.CrossRefPubMed
8.
Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.CrossRefPubMed
9.
Meijles DN, Fan LM, Ghazaly MM, et al. p22phox C242T SNP inhibits inflammatory oxidative damage to endothelial cells and vessels. Circulation. 2016;133(24):2391–403.CrossRefPubMed
10.
Carnevale R, Loffredo L, Nocella C, et al. Epicatechin and catechin modulate endothelial activation induced by platelets of patients with peripheral artery disease. Oxid Med Cell Longev. 2014;2014:691015.PubMedPubMedCentral
11.
Loffredo L, Perri L, Catasca E, et al. Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease. J Am Heart Assoc. 2014;3:e001072.CrossRefPubMedPubMedCentral
12.
El Jamali A, Valente AJ, Clark RA. Regulation of phagocyte NADPH oxidase by hydrogen peroxide through a Ca2+/c-Abl signaling pathway. Free Radic Biol Med. 2010;48:798–810.CrossRefPubMedPubMedCentral
13.
Dinauer M, Orkin S, Brown R, et al. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature. 1987;717:720.
14.
Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol. 2010;10:427–39.CrossRefPubMed
15.
Van Buul JD, Fernandez-Borja M, Anthony EC, Hordijk PL. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal. 2005;7(3–4):308–17.
16.
Touyz RM, Chen X, Tabet F, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002;90:1205–13.CrossRefPubMed
17.
Seno T, Inoue N, Gao D, et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res. 2001;103:399–409.CrossRefPubMed
18.
Pignatelli P, Sanguigni V, Lenti L, et al. gp91phox-dependent expression of platelet CD40 ligand. Circulation. 2004;110:1326–9.CrossRefPubMed
19.
Groemping Y, Lapouge K, Smerdon SJ, Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell. 2003;113:343–55.CrossRefPubMed
20.
Han CH, Freeman JLR, Lee T, et al. Regulation of the neutrophil respiratory burst oxidase: identification of an activation domain in p67(phox). J Biol Chem. 1998;273:16663–8.CrossRefPubMed
21.
Pollock JD, Williams DA, Gifford MA, et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet. 1995;9:202–9.CrossRefPubMed
22.
Quie PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest. 1967;46:668–79.CrossRefPubMedPubMedCentral
23.
Pignatelli P, Carnevale R, Di Santo S, et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol. 2011;31:423–34.CrossRefPubMed
24.
Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol. 1994;11:95–102.CrossRefPubMed
25.
Jacobson GM, Dourron HM, Liu J, et al. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res. 2003;92:637–43.CrossRefPubMed
26.
Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–23.CrossRefPubMedPubMedCentral
27.
Mollnau H, Wendt M, Szöcs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58–65.CrossRefPubMed
28.
Carlström M, Lai EY, Ma Z, et al. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am J Physiol Regul Integr Comp Physiol. 2009;296:R72–9.CrossRefPubMed
29.
Jung O, Schreiber JG, Geiger H, et al. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation. 2004;109:1795–801.CrossRefPubMed
30.
Murdoch CE, Alom-Ruiz SP, Wang M, et al. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol. 2011;106:527–38.CrossRefPubMedPubMedCentral
31.
Bendall JK, Rinze R, Adlam D, et al. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II: studies in endothelial-targeted Nox2 transgenic mice. Circ Res. 2007;100:1016–25.CrossRefPubMed
32.
Landmesser U, Cai H, Dikalov S, et al. Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002;40:511–5.CrossRefPubMedPubMedCentral
33.
Touyz RM, Mercure C, He Y, et al. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension. 2005;45:530–7.CrossRefPubMed
34.
Wang HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001;88:947–53.CrossRefPubMed
35.
Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101:1722–8.CrossRefPubMed
36.
Brooks S, Branyan D, Kayla A, et al. Pharmacological inhibition of NAD(P)H oxidase with the peptide gp91ds-tat during ischemic stroke reduces infarct volume and improves vascular reactivity in obese Zucker rats. FASEB J. 2016;30:953–1013.
37.
Girouard H, Park L, Anrather J, et al. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb. Vasc Biol. 2006;26:826–32.CrossRefPubMed
38.
Chrissobolis S, Banfi B, Sobey CG, Faraci FM. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. J Appl Physiol. 2012;113:184–91.CrossRefPubMedPubMedCentral
39.
Chan SL, Baumbach GL. Nox2 deficiency prevents hypertension-induced vascular dysfunction and hypertrophy in cerebral arterioles. Int J Hypertens. 2013;2013:793630.CrossRefPubMedPubMedCentral
40.
Wind S, Knut B, Armitage ME, et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension. 2010;56:490–7.CrossRefPubMed
41.
Rey FE, Cifuentes ME, Kiarash, et al. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res. 2001;89:408–14.CrossRefPubMed
42.
Sellers KW, Sun C, Diez-Freire C, et al. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J. 2005;19:626–8.PubMed
43.
Zhou X, Bohlen HG, Miller SJ, Unthank JL. NAD(P)H oxidase-derived peroxide mediates elevated basal and impaired flow-induced NO production in SHR mesenteric arteries in vivo. Am J Physiol Heart Circ Physiol. 2008;295:H1008–16.CrossRefPubMedPubMedCentral
44.
Zhou MS, Schulman IH, Pagano PJ, et al. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension. 2006;47:81–6.CrossRefPubMed
45.
Khan BV, Harrison DG, Olbrych MT, et al. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA. 1996;93:9114–9.CrossRefPubMedPubMedCentral
46.
Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105:1429–35.CrossRefPubMed
47.
Barry-Lane PA, Patterson C, Van Der Merwe M, et al. p47phox is required for atherosclerotic lesion progression in ApoE−/− mice. J Clin Invest. 2001;108:1513–22.CrossRefPubMedPubMedCentral
48.
Judkins CP, Diep H, Broughton BRS, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE−/− mice. Am J Physiol Heart Circ Physiol. 2010;298:H24–32.CrossRefPubMed
49.
Kirk EA, Dinauer MC, Rosen H, et al. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000;20:1529–35.CrossRefPubMed
50.
Hsich E, Segal BH, Pagano PJ, et al. Vascular effects following homozygous disruption of p47(phox): an essential component of NADPH oxidase. Circulation. 2000;101:1234–6.CrossRefPubMed
51.
Quesada IM, Lucero A, Amaya C, et al. Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques. Atherosclerosis. 2015;242:469–75.CrossRefPubMedPubMedCentral
52.
Dourron HM, Jacobson GM, Park JL, et al. Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am J Physiol Heart Circ Physiol. 2005;288:H946–53.CrossRefPubMed
53.
Weaver M, Liu J, Pimentel D, et al. Adventitial delivery of dominant-negative p67phox attenuates neointimal hyperplasia of the rat carotid artery. Am J Physiol Heart Circ Physiol. 2006;290:H1933–41.CrossRefPubMed
54.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.CrossRefPubMed
55.
Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939–45.CrossRefPubMed
56.
Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14–22.CrossRefPubMed
57.
Xiang FL, Lu X, Strutt B, et al. NOX2 deficiency protects against streptozotocin-induced beta-cell destruction and development of diabetes in mice. Diabetes. 2010;59:2603–11.CrossRefPubMedPubMedCentral
58.
Zhang M, Ay LK, Anilkumar N, et al. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation. 2006;113:1235–43.CrossRefPubMed
59.
Sukumar P, Viswambharan H, Imrie H, et al. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes. 2013;62:2130–4.CrossRefPubMedPubMedCentral
60.
Lynch CM, Kinzenbaw DA, Chen X, et al. Nox2-derived superoxide contributes to cerebral vascular dysfunction in diet-induced obesity. Stroke. 2013;44:3195–201.CrossRefPubMedPubMedCentral
61.
Bendall JK, Cave AC, Heymes C, et al. Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293–6.CrossRefPubMed
62.
Satoh M, Ogita H, Takeshita K, et al. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006;103:7432–7.CrossRefPubMedPubMedCentral
63.
Häuselmann S, Rosc-Schlüter BI, Lorenz V, et al. b1-Integrin is upregulated via Rac1-dependent reactive oxygen species as part of the hypertrophic cardiomyocyte response. Free Radic Biol Med. 2011;51:609–18.
64.
Tanaka K, Honda M, Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol. 2001;37:676–85.CrossRefPubMed
65.
Patel VB, Bodiga S, Fan D, et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension. 2012;59:1195–203.CrossRefPubMed
66.
Byrne JA, Grieve DJ, Bendall JK, et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res. 2003;93:802–4.CrossRefPubMed
67.
Grieve DJ, Byrne JA, Siva A, et al. Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol. 2006;47:817–26.CrossRefPubMed
68.
Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006;20:1546–8.CrossRefPubMed
69.
Krijnen PAJ, Meischl C, Hack CE, et al. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol. 2003;56:194–9.CrossRefPubMedPubMedCentral
70.
Fukui T, Yoshiyama M, Hanatani A, et al. Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem Biophys Res Commun. 2001;281:1200–6.CrossRefPubMed
71.
Looi YH, Grieve DJ, Siva A, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension. 2008;51:319–25.CrossRefPubMed
72.
Zhao Y, McLaughlin D, Robinson E, et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res. 2010;70:9287–97.CrossRefPubMedPubMedCentral
73.
De Falco E, Roberto C, Pagano F, et al. Role of NOX2 in mediating doxorubicin-induced senescence in human endothelial progenitor cells. Mech Ageing Dev. 2016;159:37–43.CrossRefPubMed
74.
Kahles T, Luedike P, Endres M, et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke. 2007;38:3000–6.CrossRefPubMed
75.
Chen H, Song YS, Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab. 2009;29:1262–72.CrossRefPubMedPubMedCentral
76.
Brait VH, Jackman KA, Walduck AK, et al. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab. 2010;30:1306–17.CrossRefPubMedPubMedCentral
77.
Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4–43.CrossRefPubMed
78.
Carnevale R, Loffredo L, Sanguigni V, et al. Different degrees of NADPH oxidase 2 regulation and in vivo platelet activation: lesson from chronic granulomatous disease. J Am Heart Assoc. 2014;3(3):e000920.CrossRefPubMedPubMedCentral
79.
Carnevale R, Bartimoccia S, Nocella C, et al. LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. Atherosclerosis. 2014;237:108–16.CrossRefPubMed
80.
Walsh TG, Berndt MC, Carrim N, et al. The role of Nox1 and Nox2 in GPVI-dependent platelet activation and thrombus formation. Redox Biol. 2014;2:178–86.CrossRefPubMedPubMedCentral
81.
Delaney M, Kim K, Estevez B, et al. Differential roles of the nadph-oxidase 1 and 2 in platelet activation and thrombosis. Arterioscler Thromb Vasc Biol. 2016;36:846–54.CrossRefPubMed
82.
Magwenzi S, Woodward C, Wraith KS, et al. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. Blood. 2015;125:2693–703.CrossRefPubMedPubMedCentral
83.
Krötz F, Sohn HY, Gloe T, et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002;100:917–24.CrossRefPubMed
84.
Dayal S, Wilson KM, Motto DG, et al. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation. 2013;127:1308–16.CrossRefPubMedPubMedCentral
85.
Du J, Fan LM, Mai A, Li J-M. Crucial roles of Nox2-derived oxidative stress in deteriorating insulin receptor and endothelial function in dietary obesity of mice after middle age. Br J Pharmacol. 2013;170:1064–77.CrossRefPubMedPubMedCentral
86.
Paneni F, Osto E, Costantino S, et al. Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. Circulation. 2013;127:1229–40.CrossRefPubMed
87.
Turgeon J, Haddad P, Dussault S, et al. Protection against vascular aging in Nox2-deficient mice: impact on endothelial progenitor cells and reparative neovascularization. Atherosclerosis. 2012;223:122–9.CrossRefPubMed
88.
Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–43.CrossRefPubMed
89.
Barton M. Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. Pflugers Arch. 2010;460:825–37.CrossRefPubMed
90.
Meyer MR, Fredette NC, Barton M, Prossnitz ER. Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries. Life Sci. 2014;118:213–8.CrossRefPubMedPubMedCentral
91.
Loffredo L, Perri L, Nocella C, Violi F. Antioxidant and antiplatelet activity by polyphenol-rich nutrients: focus on extra-virgin olive oil and cocoa. Br J Clin Pharmacol. 2016. doi:10.​1111/​bcp.​12923.
92.
Carnevale R, Pignatelli P, Nocella C, et al. Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. Atherosclerosis. 2014;235:649–58.CrossRefPubMed
Metadaten
Titel
The Pathophysiological Role of NOX2 in Hypertension and Organ Damage
verfasst von
Maurizio Forte
Cristina Nocella
Elena De Falco
Silvia Palmerio
Leonardo Schirone
Valentina Valenti
Giacomo Frati
Roberto Carnevale
Sebastiano Sciarretta
Publikationsdatum
01.12.2016
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 4/2016
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-016-0175-y

Weitere Artikel der Ausgabe 4/2016

High Blood Pressure & Cardiovascular Prevention 4/2016 Zur Ausgabe

Editorial

The Age of Nutraceuticals: Exploring New Therapeutic Targets

Review Article

Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?

Original Article

Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients

Original Article

Morphologic and Functional Heart Abnormalities Associated to High Modified Tei Index in Hypertensive Patients

Original Article

Long Term Home-Based Exercise is Effective to Reduce Blood Pressure in Low Income Brazilian Hypertensive Patients: A Controlled Trial

Abstracts

Abstracts from the 20th Annual Meeting of the European Council for Cardiovascular Research (ECCR), Poiano, Lake Garda, 14–16 October 2016

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise